LATEST ALERTS
Could e-cig ‘shake and vape’ be a model for sales of ingestible CBD products?
5th August 2021 - Blogs , News analysis |
There remains no certainty over the future regulation of ingestible CBD products in many jurisdictions
US federal regulation
US Postal Service ponders the post-PACT legality of continuing to ship CBD vapes
29th July 2021 - News analysis |
The US Postal Service (USPS) is still shipping CBD vape products for now – but the latest version of the Prevent All Cigarette Trafficking (PACT) Act leaves a lot of uncertainty over the exact legal position
New chair abstains as US Federal Trade Commission confirms Kushly penalty
28th July 2021 - News analysis |
A CBD company’s punishment by the US Federal Trade Commission (FTC) for making false or misleading health claims has been confirmed
Lobbyists for ‘special interests’ accused of un-American activities on cannabis
23rd July 2021 - News analysis |
Licensing issues look set to become the next big US lobbying battleground for cannabis as money moves on from the traditional legalisation-versus-prohibition field
What can be concluded from the appointment of Lina Khan as new chair of the Federal Trade Commission (FTC)?
22nd July 2021 - Blogs , News analysis |
Lina Khan’s appointment to chair the US Federal Trade Commission (FTC) – confirmed last month – was a bit of a surprise
Regulatory report: CBD as a dietary supplement in the US and EU
28th June 2021 - Regulatory reports |
As CBD grows in popularity, its regulatory status remains poorly defined. In this report CBD-Intel reviews the regulatory framework of dietary supplements and where CBD fits, or would fit, within that framework
Regulatory report: delta-8 THC in the US
19th May 2021 - Regulatory reports |
Delta-8 THC has emerged as the hottest new cannabinoid in the US market. This report examines federal law on delta-8, notes trends that are happening at state level, and discusses what the future may hold
Another CBD company that ‘should know better’ fined by US FTC over health claims
18th May 2021 - News analysis |
A CBD company has been fined more than $30,000 by the US Federal Trade Commission (FTC) in the first such punishment since a crackdown on false or misleading health claims was announced in December
Cannabis lobbying steps up in the US with major players joining the discussion
10th May 2021 - News analysis |
Significant cannabis reform is inevitably coming to congress, no matter whether the Biden administration considers it a priority, and giants in experienced lobbying industries are preparing their agents
A new head honcho for CBD policy – but who will US FDA pick for this vital role?
19th April 2021 - News analysis |
A new deputy commissioner at the US Food and Drug Administration (FDA) will likely be the single person with the most influence on the path to market for CBD in the US
Credit union runs into trouble with US agency over too-lax cannabis activities
16th April 2021 - News analysis |
Access to banking services has been a problem for the legal cannabis sector in the US from the beginning – and the experience of one cooperative in Michigan shows that the relationship can be problematic for financial institutions too
US Customs stands accused of seizing legal hemp – and farm machinery
16th April 2021 - News analysis |
The US Customs and Border Protection (CBP) agency is wrongly seizing legal hemp and hemp-related shipments – such as farm equipment that it claims constitutes drug paraphernalia – according to two recently-filed lawsuits
CBD firms find more pros than cons in legal recreational cannabis markets
6th April 2021 - News analysis |
CBD companies see more synergies than threats from the provision of legal cannabis products in states such as Colorado, which has one of the oldest recreational cannabis markets in the US
US FDA: You can’t hide health claims for CBD behind other active ingredients
31st March 2021 - News analysis |
The US Food and Drug Administration (FDA) has assessed a combined health claim for the first time and denounced the practice of promoting CBD on a product making qualified health claims based on other ingredients
US FDA warns CBD firms over inadequate testing, labelling and health claims
29th March 2021 - News analysis |
The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
Podcast: the changing regulatory environment for cannabis in the US
9th March 2021 - Podcasts , Resources |
CBD-Intel podcasts editor Jon Bruford is joined by the founder and principal of Kight Law Office, Rod Kight, a specialist in cannabis business law in the US
Wrigley’s heir goes public with $1.9bn plan to ‘transform US cannabis industry’
9th March 2021 - News analysis |
The heir to the Wrigley’s chewing gum fortune, Beau Wrigley, has entered into a deal he claims will accelerate the growth of his multi-state cannabis company, Parallel, and change the landscape of the US cannabis market
Tobacco giant Altria calls for US federal legalisation and regulation of cannabis
1st March 2021 - News analysis |
Marlboro cigarette manufacturer Altria has stated its support for the federal legalisation of cannabis – with a view to Cronos, the Canadian cannabis company in which it has a major stake, thriving in a legal US market
US state regulators’ association calls for joined-up federal thinking on cannabis
24th February 2021 - News analysis |
A US association of cannabis regulators has written to Congress urging the modernisation of cannabis policy at federal level
Will change at the FTC mean a new US approach to enforcement on CBD?
18th February 2021 - News analysis |
The US Federal Trade Commission (FTC) could take a more discerning approach to enforcement against CBD companies under the new administration in Washington
Is this the year? US cannabis and CBD law reform efforts worth watching in 2021
11th February 2021 - News analysis |
The Democratic Party, which now controls Congress and the presidency, has signalled for some time that cannabis reform is one of its top priorities, and the US public supports that reform in unprecedented numbers
All the president’s men and women sound a positive note for cannabis
10th February 2021 - News analysis |
US president Joe Biden’s appointees to a number of influential positions in the new administration give reason for optimism within the hemp and cannabis sector
US Small Business Administration claims credit for softening USDA final hemp rule
1st February 2021 - News analysis |
The US Small Business Administration (SBA) has highlighted its role in securing changes to the Department of Agriculture (USDA)’s final rule for hemp production
A brighter year ahead on cannabis rules? Our 2021 predictions for US regulation
13th January 2021 - News analysis |
CBD-Intel presents some predictions of what regulatory moves could take place around cannabis, hemp and CBD in the US in 2021
What impact do Democrat victories in both of the Georgia senate seat elections have on chances for cannabis reform at the US federal level?
8th January 2021 - Blogs |
President elect Joe Biden still looks to be somewhat reluctant to too closely embrace cannabis reform as an issue. But effective control of the senate through victories by Raphael Warnock and Jon Ossoff in special run-off elections in the state of Georgia give Democrats 48 seats with two independents that generally vote democratic (and would certainly do so on most » Continue Reading.
Georgia run-off election: it looks like good news for cannabis reform
6th January 2021 - News analysis |
Reform of cannabis laws at federal level in the US looks to be a step closer following the likely victory of the Democratic party in run-off elections for both Senate seats in the state of Georgia
It could have been so much worse: 2020 was CBD’s year in the waiting-room
1st January 2021 - News analysis |
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
A world of change – but don’t expect 2021 to deliver very much new regulation
31st December 2020 - News analysis |
Multiple jurisdictions are planning significant legislation on both CBD and hemp-related matters, but it seems regulation in 2021 could be defined as much by what doesn’t happen as by the progress made
Continuing failure to pass US federal hemp regulation leaves CBD in a tangle
29th December 2020 - News analysis |
The US Food and Drug Administration (FDA) is still working on a plan to standardise a baseline level of regulation for CBD in dietary supplements, food and drinks – but many in the industry and at state level are weary of waiting
Unfounded claims on cancer and COVID attract warning letters from US FDA
23rd December 2020 - News analysis |
Claims that CBD could help shrink tumours were among those censured by the US Food and Drug Administration (FDA) in its latest round of warning letters to the industry
US firms hit by FTC fines as Operation CBDeceit targets false health claims
21st December 2020 - News analysis |
The first ever fines – ranging up to $85,000 – have been issued to CBD companies by the US Federal Trade Commission (FTC) for deceptive marketing practices
Avazo has its collar felt by the FDA/FTC over ‘unsubstantiated COVID-19 claims’
14th December 2020 - News analysis |
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
Biden’s election should be good news for cannabis legalisation – eventually
18th November 2020 - News analysis |
With Joe Biden poised to become the 46th US president, lobbyists in Washington are scrambling to position themselves to influence cannabis policy
US federal regulation at last? It will come next year, predicts Charlotte’s Web
16th November 2020 - News analysis |
Expect US Food and Drug Administration (FDA) regulations on CBD by the second half of 2021, according to leading brand Charlotte’s Web
CBD in dietary supplements: alternative pathways to market under the US FDA
12th November 2020 - Regulatory reports |
The US Food and Drug Administration (FDA) may be open to allowing CBD as an ingredient in dietary supplements as well as in food and drink products. However, the regulatory pathway is not clear
Cannabis sector consolidates as investors join second rush for ‘green gold’
11th November 2020 - News analysis |
Investing activity in the cannabis space is on the rise, as investors take advantage of lower prices and companies seek opportunities to merge – bolstered by anticipated changes at US federal level
CBD suffering reputational damage from FDA probe and reports of bad labelling
10th November 2020 - News analysis |
Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference
Will US FDA ever publish its guidance on CBD enforcement? Who knows when?
9th November 2020 - News analysis |
It remains unclear when, or whether, US FDA guidance on CBD enforcement policy will be published, according to speakers at the recent Food and Drug Law Institute annual conference
Behind the mask: ads regulator refers claims to US Federal Trade Commission
20th October 2020 - News analysis |
The National Advertising Division (NAD) of the US Better Business Bureau has referred advertising claims made by a CBD company to the Federal Trade Commission (FTC)
Lobbyists hard at work for regulatory change as US elections approach
19th October 2020 - News analysis |
With US elections on 3rd November fast approaching, lobbyists for CBD, cannabis and hemp are eager to get their message across to candidates on both sides of the political divide
Red yeast rice and stem cells could point the way ahead for FDA regulation of CBD
16th October 2020 - News analysis |
The apparently unrelated fields of red yeast rice and stem cell research could provide clues as to how the US Food and Drug Administration (FDA) might deal with market regulation of CBD
Canada or the US: which makes the better home for your CBD or cannabis business?
8th October 2020 - News analysis |
Should CBD or cannabis companies invest in the US or Canada? There are pros and cons to each, and the same answer may not apply to everyone – or remain the same forever
A mixed blessing as US states get extra time to comply with the 2018 Farm Bill
5th October 2020 - News analysis |
The US Congress has extended by 11 months the deadline for states to get into compliance with the 2018 Farm Bill
‘We want MORE’ – US Democrats prepare for House vote on cannabis reform bill
11th September 2020 - News analysis |
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
CBD industry steps up with funding for ValidCare’s vital liver function study
7th September 2020 - News analysis |
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
What impact would the US Drug Enforcement Agency (DEA) rules have on the CBD industry if they were enacted in their current form?
4th September 2020 - Blogs |
First it’s important to note that the DEA proposals are only in a draft form and are open to comment until 20th October. They have already received a large number of comments, the majority of which appear to be criticising aspects of the proposed regulatory regime that have raised hackles among the industry.
Pharma gets bigger with approval for new cannabinoid-based treatments
3rd September 2020 - News analysis |
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
US DEA raises industry’s hackles with its strict interpretation of 0.3% THC limit
1st September 2020 - News analysis |
Proposed regulations from the US Drug Enforcement Administration (DEA) have riled the hemp and CBD sectors, with opinions divided on what the rule would mean if enacted in its current form
Charlotte’s Web denied US trademark on appeal ‘because CBD oil isn’t legal’
26th August 2020 - News analysis |
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
What can be made of Canopy’s increased interest in functional ingredients?
21st August 2020 - Blogs |
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
